# A Study of RO4917838 in Patients With Sub-optimally Controlled Symptoms of Schizophrenia (NN25307)

> **NCT01235520** · PHASE3 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 595 (actual)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** Placebo
- **DRUG:** RO4917838
- **DRUG:** RO4917838

## Key facts

- **NCT ID:** NCT01235520
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-01
- **Primary completion:** 2014-07
- **Final completion:** 2014-07
- **Target enrollment:** 595 (ACTUAL)
- **Last updated:** 2015-06-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01235520

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01235520, "A Study of RO4917838 in Patients With Sub-optimally Controlled Symptoms of Schizophrenia (NN25307)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01235520. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*